Skip to main content
Delfa

← All assets

Valproic Acid

2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

2

Ongoing

0

Recruiting

0

Completed

2

Sites

5

Countries

2

Endpoints

12

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 12 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Early Phase 1
1
Phase 2
1

Trials by status

Completed
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Memory
2
Amyloid biomarkers
2
Tau biomarkers
2
Fluid / digital biomarkers
2
Safety / tolerability / PK
2
Other (unclassified)
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 0 of 12 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

No normalized metric codes are available for this asset.

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

2 of 2

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00385710Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)

Valproic Acid

Frontotemporal dementia

Age 45-75Ph 2Completed4Jul 2010-
VPAValproic Acid in Subjects With Intact Cognition - Proof of Concept Study

Valproic Acid

Alzheimer’s disease

Age 65-90Early Ph 1Completed1Oct 2014-results

Showing 1-2 of 2 trials